Atopic Dermatitis Drugs Market Size - By Drug Class, By Route of Administration, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Atopic Dermatitis Drugs Market Introduction and Overview

According to SPER market research, 'Global Atopic Dermatitis Drugs Market Size - By Drug Class, By Route of Administration, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Atopic Dermatitis Drugs Market is predicted to reach 42.85 billion by 2034 with a CAGR of 9.28%.

Medication for atopic dermatitis aims to manage the signs and causes of this chronic inflammatory skin condition, which is characterized by redness, itching, and skin barrier dysfunction. These drugs include oral immunosuppressants and biologics for moderate to severe forms, and topical corticosteroids, calcineurin inhibitors, antihistamines, and moisturizers for milder forms.

Restraints: Despite the potential for growth, the market for atopic dermatitis medications is constrained in several ways. High treatment costs, especially for biologics and advanced targeted medications, might occasionally limit patient access, especially in low- and middle-income countries. The chronic and recurrent nature of the condition necessitates long-term treatment, which can be expensive and reduce adherence.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Drug Class, By Route of Administration, By End Use

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered AbbVie Inc., Eli Lilly and Company (Dermira), Galderma Laboratories, L.P., Incyte Corporation, LEO Pharma Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi

Global Atopic Dermatitis Drugs Market Segmentation:

By Drug Class: Based on the Drug Class, Global Atopic Dermatitis Drugs Market is segmented as; Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others.

By Route of Administration: Based on the Route of Administration, Global Atopic Dermatitis Drugs Market is segmented as; Topical, Parenteral, Oral.

By End Use: Based on the End Use, Global Atopic Dermatitis Drugs Market is segmented as; Hospital Pharmacies, Retail Pharmacies, Other Pharmacies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: PHAR2521

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1 .Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Atopic Dermatitis Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Atopic Dermatitis Drugs Market

7. Global Atopic Dermatitis Drugs Market, By Drug Class (USD Million) 2021-2034

7.1. Corticosteroids
7.2. Calcineurin Inhibitors
7.3. PDE4 Inhibitors
7.4. Biologics
7.5.Others

8. Global Atopic Dermatitis Drugs Market, By Route of Administration (USD Million) 2021-2034

8.1. Topical
8.2. Parenteral
8.3. Oral

9. Global Atopic Dermatitis Drugs Market, By End Use (USD Million) 2021-2034

9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Other Pharmacies

10. Global Atopic Dermatitis Drugs Market (USD Million) 2021-2034

10.1. Global Atopic Dermatitis Drugs Market Size and Market Share

11. Global Atopic Dermatitis Drugs Market, By Region, (USD Million) 2021-2034

11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4.J apan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America

12. Company Profile

12.1. AbbVie Inc.
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Eli Lilly and Company (Dermira)
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Galderma Laboratories, L.P.
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Incyte Corporation
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. LEO Pharma Inc.
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Novartis AG
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Otsuka Pharmaceutical Co., Ltd.
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Pfizer Inc.
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Regeneron Pharmaceuticals Inc.
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Sanofi
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others